---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087020"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:58:10.905966+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q2 net loss widens to $1.41/sh; cash >$600M after $230M raise

## Summary
- Net loss $42.6M ($1.41 loss per share) vs $26.8M ($0.90) a year ago; R&D expense doubled to $39.7M.
- Cash $340.4M at June 30, 2023; pro-forma over $600M including $230M July offering and $45M Bayer upfront.
- Strategic collaborations with Novartis (up to $1.7B milestones) and Bayer (up to $1.7B) for Bicycle radio-conjugates.
- Appointed Alethia Young as CFO effective July 17, 2023; clinical updates on BT8009 expected in 2H23.
- Preclinical data for Pb-BCY20603 BRC showed complete tumor regressions in rodent xenograft studies.

## SEC filing metadata
- accession: 0001104659-23-087020
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465923087020/0001104659-23-087020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465923087020/tm2322663d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087020
- JSON: https://secwatch.observer/filing/0001104659-23-087020.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.